Multiple sclerosis (relapsing-remitting) - dimethyl fumarate

Publication date:

Dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis
In development
Publication date
August 2014
Topic area
  • Central nervous system

Provisional Schedule

Closing date for invited submissions / evidence submission: 28 May 2013
1st appraisal committee meeting: 21 August 2013
2nd appraisal committee meeting 21 May 2014

Project Team

Technical Lead: Martyn Burke
Communications manager: Lyndsey Unwin
Project manager:

Jeremy Powell


  • Biogen Idec (dimethyl fumarate)
Patient/carer groups
  • Multiple Sclerosis Society
  • Multiple Sclerosis Trust
Professional groups
  • Association of British Neurologists
  • Institute of Neurology
  • Primary Care Neurology Society
  • Royal College of Nursing
  • Royal Collegeof Pathologists
  • Royal Collegeof Physicians
  • United Kingdom Clinical Pharmacy Association
  • United Kingdom Multiple Sclerosis Specialist Nurse Association (UKMSSNA)
  • Department of Health
  • NHS England
  • Welsh Government


  • Department of Health,Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland
Comparator manufacturer(s)
  • Bayer (interferon beta-1b) - not participating
  • Biogen Idec (interferon beta-1a natalizumab)
  • Merck Serono (interferon beta-1a)
  • Novartis Pharmaceuticals UK ( interferon beta-1b, fingolimod)
  • Teva Pharmaceuticals (glatiramer acetate)
Relevant research groups
  • None
Evidence Review Group
  • NHS Centre for Reviews and Dissemination and Centre for Health Economics- York
  • National Institute for Health Research Health Technology Assessment Programme
Associated Guideline Groups
  • National Clinical Guideline Centre
Associated Public Health Groups
  • None


13 December 2013
The release of documents following the 21 August Technology Appraisal Committee meeting has been delayed because the marketing authorisation for dimethyl fumarate has not yet been granted.
Get involved